Evidence mapPaperPMID 36833359Full record

ReviewGenes2023

Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review.

Claudia Maria Jurca, Kinga Kozma, Codruta Diana Petchesi, Dana Carmen Zaha, Ioan Magyar, Mihai Munteanu, Lucian Faur, Aurora Jurca, Dan Bembea, Emilia Severin and 1 more

Open access · goldFull text readReviewCase Reports
In one paragraph

Review in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Claudia Maria JurcaDepartment of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410081 Oradea, Romania.
Kinga KozmaDepartment of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410081 Oradea, Romania.ORCID 0000-0002-6276-0094
Codruta Diana PetchesiDepartment of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410081 Oradea, Romania.ORCID 0000-0002-8442-6791
Dana Carmen ZahaDepartment of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410081 Oradea, Romania.ORCID 0000-0003-4021-4989
Ioan MagyarDepartment of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410081 Oradea, Romania.
Mihai MunteanuDepartment of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410081 Oradea, Romania.ORCID 0000-0002-4538-7574
Lucian FaurDepartment of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410081 Oradea, Romania.
Aurora JurcaFaculty of Medicine and Pharmacy, University of Oradea, 410081 Oradea, Romania.
Dan BembeaFaculty of Medicine, University of Medicine and Pharmacy "Iuliu Hațieganu", 400012 Cluj Napoca, Romania.
Emilia SeverinDepartment of Genetics, University of Medicine and Pharmacy "Carol Davila", 020021 Bucharest, Romania.
Alexandru Daniel JurcaDepartment of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410081 Oradea, Romania.
University of Oradea · ROCarol Davila University of Medicine and Pharmacy · ROIuliu Hațieganu University of Medicine and Pharmacy · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberous sclerosis complex (TSC) is a rare autosomal dominant neurocutaneous syndrome. It is manifested mainly in cutaneous lesions, epilepsy and the emergence of hamartomas in several tissues and organs. The disease sets in due to mutations in two tumor suppressor genes:

Indexed as

Diabetes Mellitus, Type 2EpilepsyMetforminTuberous SclerosisAdolescentAdultFemaleHumansInfantPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSeizuresSignal TransductionTOR Serine-Threonine KinasesTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinMetforminMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinTumor Suppressor ProteinsepilepsyhamartomasMetforminTSC1TSC2tuberous sclerosistype 2 diabetes mellitus

Identifiers

PMID36833359
PMCPMC9957184
OpenAlexW4319758900

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.